These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36958476)

  • 1. Perspective insights of small molecules, phytoconstituents and biologics in the management of psoriasis: A focus on targeting major inflammatory cytokine pathways.
    Kadagothy H; Nene S; Amulya E; Vambhurkar G; Rajalakshmi AN; Khatri DK; Singh SB; Srivastava S
    Eur J Pharmacol; 2023 May; 947():175668. PubMed ID: 36958476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etiology and Pathogenesis of Psoriasis.
    Boehncke WH
    Rheum Dis Clin North Am; 2015 Nov; 41(4):665-75. PubMed ID: 26476225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review.
    Lee TL; Tsai TF
    Inflamm Res; 2022 Feb; 71(2):157-168. PubMed ID: 34981130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints.
    Boutet MA; Nerviani A; Gallo Afflitto G; Pitzalis C
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29425183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What's New in Psoriasis.
    von Csiky-Sessoms S; Lebwohl M
    Dermatol Clin; 2019 Apr; 37(2):129-136. PubMed ID: 30850034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases.
    Kaufman BP; Alexis AF
    Curr Allergy Asthma Rep; 2018 Aug; 18(10):55. PubMed ID: 30171358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis: Recent progress in molecular-targeted therapies.
    Honma M; Hayashi K
    J Dermatol; 2021 Jun; 48(6):761-777. PubMed ID: 33404109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review.
    Kamata M; Tada Y
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32121574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine alterations in psoriasis: an updated review.
    Seyedmirzaei H; Rezaei N
    Expert Rev Clin Immunol; 2021 Dec; 17(12):1323-1335. PubMed ID: 34845948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the efficacy of biologics and clinical plaque psoriasis subtypes in Japanese patients: A single-center pilot study.
    Ito K; Bayaraa B; Imafuku S
    J Dermatol; 2019 Dec; 46(12):1160-1165. PubMed ID: 31556161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Product-Derived Compounds Targeting Keratinocytes and Molecular Pathways in Psoriasis Therapeutics.
    Lee YG; Jung Y; Choi HK; Lee JI; Lim TG; Lee J
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From Empirical to Pathogenesis-Based Treatments for Psoriasis.
    van de Kerkhof PC
    J Invest Dermatol; 2022 Jul; 142(7):1778-1785. PubMed ID: 35249726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics for psoriasis: What is new?
    Özyurt K; Ertaş R; Atasoy M
    Dermatol Ther; 2019 May; 32(3):e12916. PubMed ID: 30972872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Case of Psoriasis Complicated by Breast Cancer after Systemic Treatments Including Biologics.
    Morizane S; Sugimoto S; Motoki T; Katayama N; Omori M; Iwatsuki K
    Acta Med Okayama; 2018 Apr; 72(2):185-187. PubMed ID: 29674768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
    Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
    J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy.
    Mashiko S; Edelmayer RM; Bi Y; Olson LM; Wetter JB; Wang J; Maari C; Saint-Cyr Proulx E; Kaimal V; Li X; Salte K; Garcet S; Kannan AK; Huang SM; Cao X; Liu Z; Krueger JG; Sarfati M; Bissonnette R; Smith KM
    J Invest Dermatol; 2020 May; 140(5):1015-1025.e4. PubMed ID: 31715177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Developments in the Immunology of Psoriasis.
    Grän F; Kerstan A; Serfling E; Goebeler M; Muhammad K
    Yale J Biol Med; 2020 Mar; 93(1):97-110. PubMed ID: 32226340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis.
    D'Urso DF; Chiricozzi A; Pirro F; Calabrese L; Caldarola G; Fossati B; De Simone C; Peris K
    G Ital Dermatol Venereol; 2020 Aug; 155(4):411-420. PubMed ID: 32545945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis.
    Sun C; Xia J
    Minerva Med; 2020 Jun; 111(3):254-265. PubMed ID: 32166932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Insights in Psoriasis Management using Herbal Drug Nanocarriers.
    Salgaonkar SP; Purewal JS; Doshi GM; Gharat S; Fernandes T; Sawarkar SP
    Curr Pharm Des; 2024 Jul; ():. PubMed ID: 39051579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.